Teva Oncology offers a resource called CORE®
(Comprehensive Oncology Reimbursement Expertise).

CORE provides support as well as online tools to help make it easier to understand the reimbursement process

The CORE hotline (1-888-587-3263) can help:

  • Verify benefits and coverage
  • Offer precertification and prior authorization support
  • Explain coverage guidelines
  • Provide support through the claims and appeals process
  • Identify programs that may be able to help you pay for treatment
enroll in CORE
  • Phone
    Call 1-888-587-3263
    M–F, 9 am–8 pm (ET)

  • Fax
    Complete the CORE enrollment form and fax to 1-866-676-4073

  • Visit
    www.TevaCORE.com

Patient assistance program

The Teva Cares Foundation Patient Assistance Program provides certain Teva medications at no cost to eligible patients in the United States. Eligibility is based on patients’ income and prescription insurance status.

Please click here to review the Teva Cares Foundation Patient Assistance Programs eligibility requirements to determine if you qualify, or call 877-237-4881. We are staffed to assist you Monday through Friday, from 9 am to 8 pm (ET).

If you do not meet the eligibility requirements for the Teva Cares Foundation Patient Assistance Programs, Teva may offer a reimbursement assistance program or other type of program to assist you. For more information, please call 1-888-TEVA-USA (838-2872).

Some patients may be eligible for assistance from other programs. Click here for other assistance programs.

Insurance coverage

Here are some commonly used terms and tips to help make the reimbursement process easier:

  • Reimbursement is the process of getting payment from an insurance plan for drugs already paid for
  • Prior authorization is the process of getting approval from an insurance plan for a medication or service before receiving it. Some insurance plans may require prior authorization for Teva Oncology products
  • Make sure that your doctor's office has your most current insurance information
  • Typically, your doctor’s office submits all paperwork, but you may need to update your patient information at your doctor's office
  • If you don’t have insurance coverage, and have difficulty affording your treatment, contact the CORE hotline at 1-888-587-3263
  • CORE (Comprehensive Oncology Reimbursement Expertise) is a convenient reimbursement resource for patients and their health care providers. CORE provides a reimbursement support program along with online tools and resources. You can find information on the CORE website or by calling the CORE hotline at 1-888-587-3263
  • There are many reasons why insurance plans issue denials. It could be that a prior authorization was not initiated with your insurance plan. The plan may also deny the request due to lack of medical documentation to support treatment. Whatever the reason, you may be able to file an appeal. See the Reimbursement Process page for an example of how the process works
  • An appeal is a request for reconsideration of services that were denied reimbursement by an insurance plan. An appeal is filed if the insurance plan does not pay or does not pay enough for a procedure or service. The appeal is made to the insurance plan and there are usually specific guidelines
  • The amount of time an insurance plan has to respond to an appeal request varies by plan, but insurance plans usually have 30 to 45 days to respond to an appeal request

Infuse in about 10 minutes

Learn how BENDEKA® is given

MORE
LESS

Approved Use

BENDEKA is indicated for the treatment of patients with

  • Chronic lymphocytic leukemia (CLL). Efficacy relative to first-line therapies other than chlorambucil has not been established.

  • Indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within 6 months of treatment with rituximab or a rituximab-containing regimen.

Important Safety Information

BENDEKA (bendamustine HCl) injection is not right for everyone, including patients with a known allergic response to bendamustine, polyethylene glycol 400, propylene glycol, or monothioglycerol.

BENDEKA may cause serious side effects including: low blood cell counts, infections or recurrence of infections, unexpected responses to BENDEKA when placed in your blood, sudden and severe allergic responses, kidney failure due to fast breakdown of cancer cells, other cancers, and leaking of BENDEKA out of your vein and into your surrounding skin. Some of these side effects, such as low blood counts, infections, liver injury, and severe allergic skin responses (when bendamustine HCl was given alone and in combination with other anticancer medications or allopurinol), have caused death.

Tell your doctor if you have any side effects including: rash, facial swelling, or difficulty breathing during or soon after your infusion with BENDEKA injection. These are signs of an allergic reaction. You also should tell your doctor if you have shortness of breath, significant fatigue, bleeding, bruising, fever, or other signs of infection. Also, tell your doctor if you experience nausea, vomiting, diarrhea, loss of appetite, or a yellow skin tone. In addition, your doctor will perform blood tests to see if you have low blood counts. These are lower-than-normal numbers of red blood cells, white blood cells, or platelets.

Some serious side effects may require changes in therapy, such as lowering the amount of BENDEKA given, stopping the use of BENDEKA, or waiting longer than expected between doses of BENDEKA.

BENDEKA may cause fetal harm if taken while pregnant. Women should avoid becoming pregnant or nursing while receiving BENDEKA.

Non–blood-related side effects may occur including: fever, nausea, and vomiting, diarrhea, constipation, loss of appetite, cough, headache, weight loss, difficulty breathing, rash, and mouth irritation.

Blood-related side effects may occur including: low red blood cells (oxygen-carrying cells), low platelets (blood-clotting cells), and decreased number of three different types of white blood cells (infection-fighting cells).

These are not all of the possible side effects of BENDEKA. For more information ask your healthcare provider.

You are encouraged to report side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

For more information about BENDEKA, ask your doctor, or call 1-800-896-5855.

This information does not take the place of talking with your doctor for medical advice about your condition or treatment.

Please read the Full Prescribing Information.

BENDEKA® is a registered trademark of Cephalon, Inc.
©2017 Cephalon, Inc., a wholly-owned subsidiary of Teva Pharmaceutical Industries Ltd.
All rights reserved. BEN-40430 June 2017.

The information presented on this Web site is intended for US residents only.

MORE
LESS

Approved Use

BENDEKA is indicated for the treatment of patients with

  • Chronic lymphocytic leukemia (CLL). Efficacy relative to first-line therapies other than chlorambucil has not been established.

  • Indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within 6 months of treatment with rituximab or a rituximab-containing regimen.

Important Safety Information

BENDEKA (bendamustine HCl) injection is not right for everyone, including patients with a known allergic response to bendamustine, polyethylene glycol 400, propylene glycol, or monothioglycerol.

BENDEKA may cause serious side effects including: low blood cell counts, infections or recurrence of infections, unexpected responses to BENDEKA when placed in your blood, sudden and severe allergic responses, kidney failure due to fast breakdown of cancer cells, other cancers, and leaking of BENDEKA out of your vein and into your surrounding skin. Some of these side effects, such as low blood counts, infections, liver injury, and severe allergic skin responses (when bendamustine HCl was given alone and in combination with other anticancer medications or allopurinol), have caused death.

Tell your doctor if you have any side effects including: rash, facial swelling, or difficulty breathing during or soon after your infusion with BENDEKA injection. These are signs of an allergic reaction. You also should tell your doctor if you have shortness of breath, significant fatigue, bleeding, bruising, fever, or other signs of infection. Also, tell your doctor if you experience nausea, vomiting, diarrhea, loss of appetite, or a yellow skin tone. In addition, your doctor will perform blood tests to see if you have low blood counts. These are lower-than-normal numbers of red blood cells, white blood cells, or platelets.

Some serious side effects may require changes in therapy, such as lowering the amount of BENDEKA given, stopping the use of BENDEKA, or waiting longer than expected between doses of BENDEKA.

BENDEKA may cause fetal harm if taken while pregnant. Women should avoid becoming pregnant or nursing while receiving BENDEKA.

Non–blood-related side effects may occur including: fever, nausea, and vomiting, diarrhea, constipation, loss of appetite, cough, headache, weight loss, difficulty breathing, rash, and mouth irritation.

Blood-related side effects may occur including: low red blood cells (oxygen-carrying cells), low platelets (blood-clotting cells), and decreased number of three different types of white blood cells (infection-fighting cells).

These are not all of the possible side effects of BENDEKA. For more information ask your healthcare provider.

You are encouraged to report side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

For more information about BENDEKA, ask your doctor, or call 1-800-896-5855.

This information does not take the place of talking with your doctor for medical advice about your condition or treatment.

Please read the Full Prescribing Information.